Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Core Points - Calidi Biotherapeutics Inc. has appointed Eric Poma, Ph.D. as the new Chief Executive Officer and granted him a stock option for 726,412 shares at an exercise price of $0.469, which reflects the closing price on April 22, 2025 [1][2] - The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in equal monthly installments until April 22, 2029 [2] - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted antitumor virotherapies using allogeneic stem cells to enhance the efficacy and safety of oncolytic viruses for treating various cancers [3]